The characterization of the in vitro metabolites of toad venom, which has been widely used as a traditional Chinese drug, Ch'an Su, has been completed. Toad venom contains bufotoxin (such as marinobufotoxin; marinobufagin 3-suberoylarginine ester) and bufogenin (such as marinobufagin, bufalin) as the main cardiac steroids. An in vitro experiment using the rat or human liver cytosolic fraction disclosed that marinobufotoxin produced marinobufagin, but not its 3-hemisuberate. Marinobufagin was subjected to the enzyme reaction using the rat or human liver microsomal fraction together with NADPH and NAD, which produced 3-dehydromarinobufagin and 3-epimarinobufagin. Marinobufagin produced its 3-sulfate upon treatment with the rat or human liver cytosolic fraction and 3'-phosphoadenosine 5'-phosphosulfate.
vitro experiment using the rat or human liver cytosolic fraction disclosed that marinobufotoxin produced marinobufagin, but not its 3-hemisuberate. Marinobufagin was subjected to the enzyme reaction using the rat or human liver microsomal fraction together with NADPH and NAD, which produced 3-dehydromarinobufagin and 3-epimarinobufagin. Marinobufagin produced its 3-sulfate upon treatment with the rat or human liver cytosolic fraction and 3'-phosphoadenosine 5'-phosphosulfate.
Bufalin was also subjected to the above enzyme reactions and showed almost the same results except for the result that the hydroxylation has occurred at 5β-position. On the other hand, small amounts of marinobufagin 3-glucuronide were obtained only by treatment with the human liver microsomal fraction and uridine 5'-diphosphoglucuronic acid. The structures of these metabolites were confirmed using authentic samples regarding their high performance liquid chromatographic behavior and/or liquid chromatography-mass spectrometry analysis.
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INTRODUCTION
Digitalis glycosides, represented by digoxin and digitoxin having a five-member lactone ring at the 17β-position of the steroid (cardenolide), have been commonly used for the treatment of congestive heart failure and other cardiac diseases. The metabolic fates of these glycosides have already been clarified (Volp and Lage, 1978; Gault et al., 1982; Ohta et al., 1984) . On the other hand, toad venom has also been widely used as a traditional Chinese drug, Ch'an Su, where the bufotoxin and bufogenin having a sixmember lactone ring at the 17β-position of the steroid (bufadienolide) are the main cardiac steroids (Shimada et al., 1977) . The metabolic fate of bufogenin (such as bufalin and cinobufagin) has been studied, and the 3-epimer has been obtained via the 3-dehydro compound (Tóma et al., 1987; Shimada et al., 1989; Zhang et al., 1990; Zhang et al., 1991; Shimizu and Morishita, 1996) together with the other hydroxylated compounds, but the position of the introduced hydroxy group still remains unclear (Tóma et al., 1991) . Furthermore, the metabolic pathway of bufotoxin (bufogenin 3-suberoylarginine ester) and the phase II metabolites of bufogenin have not been
clarified. The metabolism of toad venom, especially bufotoxin, has been poorly investigated in spite of the historic age of Ch'an Su as shown above.
In this study, we have clarified the in vitro metabolites of the representative bufotoxin, marinobufotoxin (marinobufagin 3-suberoylariginine ester), together with its genin, marinobufagin (Shimada et al., 1977) (Fig. 1a) . In comparison, those of the representative bufogenin, bufalin, were also studied (Fig. 1b) . The structures of these metabolites were confirmed using authentic samples regarding their high performance liquid chromatographic behavior and/or liquid chromatography-mass spectrometry (LC/MS) analysis.
EXPERIMENTAL
Animals and chemicals. Wistar strain rats (male, 7weeks old) were obtained from Japan SLC (Hamamatsu, Japan). 3'-Phosphoadenosine 5'-phosphosulfate (PAPS) and uridine 5'-diphosphoglucuronic acid (UDPGA) were obtained from Sigma-Aldrich (St.
Louis, MO, USA) and Nacalai Tesque (Kyoto, Japan), respectively. Marinobufotoxin, marinobufagin 3-hemisuberate, marinobufagin, bufalin and telocinobufagin were obtained from the Japanese toad venom (Shimada et al., 1977 were used as the solvent and the internal standard, respectively.
Synthesis of authentic samples. 3-Epimarinobufagin and 3-dehydromarinobufagin were synthesized in our laboratories according to the known procedure (Pettit and Kamano, 1972 The sulfates of bufogenin and its 3-epimer were synthesized in our laboratories according to the known procedure (Shimada et al., 1977 Enzyme sources. The pooled human liver microsomal and cytosolic fractions were purchased from Xenotech LLC (Lenex, KS, USA). Rat liver tissues were homogenized in three volumes of 0.25 M sucrose and the homogenate was centrifuged at 9,000g for 20 min. The supernatant was further centrifuged at 105,000g for 60 min. The 9,000g and 105,000g supernatants were used as the rat liver S9 fraction and the rat liver cytosolic fraction, respectively. The precipitate obtained from the centrifugation at 105,000g
was used as the rat liver microsomal fraction. The protein concentration was measured by the method of Bradford using bovine serum albumin as the standard (Bradford, 1976) .
Enzymatic hydrolysis of marinobufotoxin. Marinobufotoxin (up to 100 μM final concentration in the incubation medium, from a stock solution in methanol) was added to the assay mixture (total volume of 1.0 mL) containing 1 mg protein of the rat or human liver cytosolic fraction in Tris-HCl buffer (pH 7.4, 50 mM) containing EDTA (2 mM). The assay mixture was incubated at 37℃ for 3 h. After the incubation, the reaction was terminated by the addition of ethyl acetate (2 mL). After extraction with ethyl acetate, the ethyl acetate layer was washed with H2O and evaporated to dryness under a N2 gas stream. The residue was dissolved in methanol (100 μL ) and subjected to HPLC.
Analysis of phaseⅠmetabolites of bufogenin. Marinobufagin or bufalin (up to 100 μM final concentration in the incubation medium, from a stock solution in methanol) was added to the assay mixture (total volume of 0.5 mL) containing 1 mg protein of the rat or human liver microsomal fraction in Tris-HCl buffer (pH 7.4, 50 mM) containing NAD and NADPH (each 100 μM). The assay mixture was incubated at 37℃ for 3 h. After the incubation, the reaction was terminated by the addition of ethyl acetate (2 ml).
After extraction with ethyl acetate, the ethyl acetate layer was washed with H2O and evaporated to dryness under a N2 gas stream. The residue was dissolved in methanol (50 μL ) and subjected to HPLC.
Sulfation assay. Marinobufagin, 3-epimarinobufagin or bufalin (up to 50 μM final concentration in the incubation medium, from a stock solution in methanol) was added to the assay mixture (total volume of 0.5 mL) containing 0.5 mg protein of the rat or human liver cytosolic fraction in Tris-HCl buffer (pH 7.4, 50 mM) containing 1,4-dithiothreitol (DTT, 50 μM), MgCl2 (5 mM) and PAPS (149 μM). The assay mixture was incubated at 37℃ for 2 h. After the incubation, the reaction was terminated by heating for 5 min. After centrifugation at 1,500g for 10 min, the supernatant was passed through a Strata-X cartridge. After washing with H2O (2 mL) and ethyl acetate (2 mL), the conjugate was eluted with methanol (2 mL). The methanol layer was evaporated to dryness under a N2 gas stream. The residue was dissolved in methanol (50 μL) and subjected to HPLC and/or LC/MS analysis. The authentic marinobufagin 3-sulfate (ca. 1 μg/tube) was quantitatively recovered (103%, n=2).
Glucuronidation assay. Marinobufagin or 3-epimarinobufagin (up to 50 μM final concentration in the incubation medium, from a stock solution in methanol) was added to the assay mixture (total volume of 0.5 mL) containing 0.5 mg protein of the rat or human liver microsomal fraction in Tris-HCl buffer (pH 7.4, 50 mM) containing EDTA
(1 μM), MgCl2 (5 mM), 0.05% Triton X-100 and UDPGA (4 mM). The assay mixture was incubated at 37℃ for 2 h. After the incubation, the reaction was terminated by heating for 5 min. After centrifugation at 1,500g for 10 min, the supernatant was passed through a Strata-X cartridge. After washing with H2O (2 mL) and ethyl acetate (2 mL), the conjugate was eluted with methanol (2 mL). The methanol phase was evaporated to dryness under a N2 gas stream. The residue was dissolved in methanol (50 μL) and subjected to the LC/MS analysis.
RESULTS AND DISCUSSION
The characterization of in vitro metabolites of toad venom, bufotoxin and bufogenin, has been done using HPLC and/or LC/MS. The approximate conversion and recovery rates were calculated using an authentic sample regarding its UV absorption intensity at 300 nm in HPLC/UV.
Enzymatic hydrolysis of marinobufotoxin
Marinobufotoxin was subjected to enzymatic hydrolysis using the rat or human liver cytosolic fraction. The incubation mixture was extracted with ethyl acetate. It was reported that marinobufagin and marinobufagin 3-hemisuberate was obtained from incubation mixture using hog pancreas lipase as an enzyme source by ethyl acetate extraction (Shimada et al., 1977) . About 10% of the marinobufotoxin produced marinobufagin, which was confirmed using an authentic sample regarding its HPLC chromatographic behavior [MeOH-0.5% AcONa (pH 5.0 adjusted with AcOH)(5:4), marinobufagin (tR 5.8 min), marinobufotoxin (tR 6.8 min); MeCN-0.5% AcONa (pH 5.0 adjusted with AcOH)(2:3), marinobufagin (tR 5.6 min)], but marinobufagin 3-hemisuberate has not been obtained [MeOH-0.5% AcONa (pH 5.0 adjusted with AcOH)(5:3), tR 9.0 min]. Even if the incubation time was reduced to ten min, marinobufagin 3-hemisuberate has not been obtained. The treatment of marinobufotoxin with the rat liver S9 fraction or microsomal fraction gave almost the same results. These data showed that the enzyme reacted at the ester (-COOR) group rather than at the acid amide (-CONH-) group.
Analysis of phaseⅠmetabolites of bufogenin
Marinobufagin was subjected to an enzymatic reaction using the rat liver microsomal fraction in the presence of NAD and NADPH. The residue obtained from the incubation mixture was subjected to HPLC using MeCN-H2O (1:2) as the mobile phase.
3-Dehydromarinobufagin (tR 8.4 min) and 3-epimarinobufagin (tR 5.1 min) were confirmed using authentic samples regarding their chromatographic behavior together with the substrate (tR 11.7 min). These were also confirmed by inclusion chromatography containing γ-cyclodextrin (CD)[MeOH-H2O (1:1) containing γ-CD (4 mM); 3-epimarinobufagin (tR 5.6 min), 3-dehydromarinobufagin (tR 6.3 min), marinobufagin (tR 7.2 min)] (Fig. 2a) . The treatment of marinobufagin with the human liver microsomal fraction gave almost the same result. The treatment of 3-dehydromarinobufagin with the rat liver microsomal fraction in the presence of NAD and NADPH as described above gave not only 3-epimarinobufagin (ca. 20%) but also marinobufagin (ca. 12%).
The representative bufogenin, bufalin, was also subjected to the reaction using the rat or human liver microsomal fraction to produce the 3-epimer together with bufalone [HPLC, Chromolith Performance RP-18e (100 x 4.6 mm i.d.; Merck, Darmstadt, Germany), MeOH-H2O (12:13); 3-epibufalin (tR 14.0 min), bufalone (tR 11.5 min), bufalin (tR 12.6 min)]. These data are compatible with our previous results using the rat liver homogenate in the presence of NADPH and NAD (Shimada et al., 1989) . About 30% of bufalin produced the new metabolite, telocinobufagin (Fig. 1b) , upon treatment with the human liver microsomal fraction in the presence of co-factors, which was confirmed using an authentic sample regarding its HPLC chromatographic behavior [MeOH-H2O
(11:9) containing γ-CD (2 mM), tR 8.9 min; Chromolith Performance RP-18e, MeOH-H2O (12:13) tR 7.9 min (Fig. 2b) ; Develosil 60-5 (5 μm, 250 x 4.6 mm i.d.; Nomura, Seto, Japan), AcOEt-isopropanol (95:5), tR 7.1 min]. It was reported that digitoxigenin (cardenolide) having a five-member lactone ring instead of the six-member one (bufadienolide) was metabolized to the 5β-hydroxylated metabolite (periplogenin) upon treatment with the rabbit liver homogenate (Bulger and Stohs, 1973) , which is compatible to the above results. On the other hand, about 1% of bufalin produced telocinobufagin upon treatment with the rat liver microsomal fraction in the presence of co-factors and the main metabolite was 3-epimer (about 90% from the substrate).
These different data obtained from rat and human demonstrated the differences in 7 different species.
All of the above data showed that bufogenin having the 3β-hydroxy-5β-structure is enzymatically metabolized to the inactive metabolite having the 3α-hydroxy-5β-structure (Nambara et al., 1972) together with hydroxylation such as at 5β-position to give telocinobufagin.
Sulfation assay. Marinobufagin or 3-epimarinobufagin was treated with the rat or human liver cytosolic fraction together with PAPS. After the incubation, the reaction mixture was passed through a Strata-X cartridge. The substrate was washed out with ethyl acetate, and the conjugate was eluted with methanol. The residue obtained from the incubation mixture was subjected to HPLC and LC/MS analysis. Marinobufagin produced the 3-sulfate which was confirmed using an authentic sample regarding its HPLC chromatographic behavior [MeOH-5 mM HCO2NH4 (pH 5.0 adjusted with HCO2H) (2:3); tR 9.1 min] (Fig. 3a) and LC/ESI-MS analysis (Fig. 3b) . However, the 3-epimarinobufagin did not produce the respective 3-sulfate, which was confirmed using an authentic sample regarding its HPLC chromatographic behavior [MeOH-5 mM HCO2NH4 (pH 5.0 adjusted with HCO2H) (2:3); tR 7.1 min]. Bufalin was also subjected to the sulfation reaction to produce the sulfate, which was confirmed using an authentic sample regarding its chromatographic behavior [HPLC, MeOH-5 mM HCO2NH4 (pH 5.0 adjusted with HCO2H) (2:3); tR 12.5 min] (Fig. 4a) and LC/ESI-MS analysis (Fig. 4b) .
Glucuronidation assay. Marinobufagin or 3-epimarinobufagin was treated with the rat or human liver microsomal fraction in the presence of UDPGA. The residue obtained from the incubation mixture was subjected to an LC/ESI-MS analysis [MeOH-5 mM HCO2NH4 (pH 5.0 adjusted with HCO2H) (2:3), tR 9.2 min]. Marinobufagin produced small amounts of 3-glucuronide (less than 1 %) only by treatment with the human liver microsomal fraction (Fig. 5) . The respective glucuronide has not been obtained under the other conditions.
All the above data suggested the following in vitro metabolic pathway of marinobufotoxin using the rat or human liver as an enzyme source as shown in Fig. 6 .
Marinobufotoxin was hydrolyzed to marinobufagin, which was transformed into the 3-epimer possibly via the 3-dehydro compound. Instead of glucuronidation, sulfation mainly occurred on marinobufagin to produce the marinobufagin 3-sulfate as the phase II metabolite of bufogenin. The data showed that bufogenin is enzymatically metabolized to the biologically inactive sulfate (Shimada et al., 1985) . The representative bufogenin, bufalin, showed the similar metabolic pathway as marinobufagin. But it is noteworthy that telocinobufagin was obtained from bufalin upon treatment with the human and rat liver microsomal fraction in the presence of NADPH and NAD, which means hydroxylation occurred at 5β-position like the metabolic pathway of digitoxigenin (Bulger and Stohs, 1973) .
Further experiments including the in vivo one are now in progress in our laboratories in order to clarify the metabolic pathway of bufotoxin and bufogenin. Fig. 6 . K. Shimada et al. 
